Positive antibody screen in pregnancy

By trimester

Weeks 1–13

1st trimester

ABO, RhD, and red-cell antibody screening is performed at the initial prenatal visit. A positive result needs antibody identification because anti-D is only one possibility and antibodies differ in their ability to affect fetal red cells.

Weeks 14–27

2nd trimester

For a clinically significant antibody, the plan may include serial titers and assessment of whether the fetus carries the relevant antigen. A critical titer signals the need for specialist follow-up; it does not predict the newborn's outcome by itself.

Weeks 28–birth

3rd trimester

Anti-D can appear after routine Rh immune globulin and remain detectable for months. If true alloimmunization or another significant antibody is present, fetal assessment may include middle cerebral artery Doppler, with timing based on antibody type, history, and fetal antigen status.

What does the evidence show for positive antibody screen?

• A positive red-cell antibody screen requires antibody identification because Rh and Kell antibodies are among those that can cause fetal anemia, while Rh-positive patients can still have non-D antibodies. 1
• When anti-D first appears after Rh immune globulin, it should initially be considered passive; no single laboratory test clearly separates passive from immune anti-D, so timing, records, and whether the antibody weakens over time matter. 2
• Clinically significant antibodies are commonly followed with titers every two to four weeks; reaching a critical titer is a referral signal for high-risk fetal assessment, not a measurement of fetal anemia or a prediction of neonatal outcome. 2
• Updated alloimmunization guidance incorporates fetal red-cell antigen testing and middle cerebral artery peak systolic velocity Doppler to identify an antigen-positive fetus and assess for fetal anemia before deciding whether invasive care is needed. 3
• Current SMFM guidance states that Rh immune globulin is for RhD-negative, antibody-screen-negative patients at indicated times; it does not address sensitization to other red-cell antigens, and cell-free fetal antigen genotyping requires counseling about its limits. 4

When should I call my provider about positive antibody screen?

A positive antibody screen itself does not cause an emergency symptom, but do not miss the follow-up laboratory or maternal-fetal medicine plan. If you are RhD-negative, contact your obstetric team promptly after vaginal bleeding, abdominal trauma, amniocentesis, chorionic villus sampling, or another potentially sensitizing event because Rh immune globulin timing may matter when you are not already sensitized. Heavy bleeding, severe abdominal pain, fainting, or reduced fetal movement needs urgent assessment. If you are ever unsure which side of the line you are on, make the call. Obstetric teams handle these check-ins as routine, not as overreacting.